Shandong Sinobioway Biomedicine Co Ltd (002581) - Net Assets
Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) has net assets worth CN¥1.99 Billion CNY (≈ $291.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.21 Billion ≈ $324.07 Million USD) and total liabilities (CN¥221.51 Million ≈ $32.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore balance sheet size of Shandong Sinobioway Biomedicine Co Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.99 Billion |
| % of Total Assets | 90.0% |
| Annual Growth Rate | 20.58% |
| 5-Year Change | -7.68% |
| 10-Year Change | -5.67% |
| Growth Volatility | 75.96 |
Shandong Sinobioway Biomedicine Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Shandong Sinobioway Biomedicine Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below shows the annual net assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024. For live valuation and market cap data, see Shandong Sinobioway Biomedicine Co Ltd (002581) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.02 Billion ≈ $295.93 Million |
-6.97% |
| 2023-12-31 | CN¥2.17 Billion ≈ $318.08 Million |
-11.94% |
| 2022-12-31 | CN¥2.47 Billion ≈ $361.21 Million |
-0.04% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.34 Million |
+12.72% |
| 2020-12-31 | CN¥2.19 Billion ≈ $320.56 Million |
-8.30% |
| 2019-12-31 | CN¥2.39 Billion ≈ $349.56 Million |
-15.29% |
| 2018-12-31 | CN¥2.82 Billion ≈ $412.66 Million |
-3.37% |
| 2017-12-31 | CN¥2.92 Billion ≈ $427.04 Million |
+15.47% |
| 2016-12-31 | CN¥2.53 Billion ≈ $369.84 Million |
+17.89% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.71 Million |
+186.07% |
| 2014-12-31 | CN¥749.40 Million ≈ $109.66 Million |
+1.50% |
| 2013-12-31 | CN¥738.31 Million ≈ $108.04 Million |
+4.81% |
| 2012-12-31 | CN¥704.41 Million ≈ $103.08 Million |
+4.78% |
| 2011-12-31 | CN¥672.28 Million ≈ $98.38 Million |
+279.09% |
| 2010-12-31 | CN¥177.34 Million ≈ $25.95 Million |
+36.73% |
| 2009-12-31 | CN¥129.71 Million ≈ $18.98 Million |
+11.70% |
| 2008-12-31 | CN¥116.12 Million ≈ $16.99 Million |
+38.34% |
| 2007-12-31 | CN¥83.94 Million ≈ $12.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Sinobioway Biomedicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1254.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥675.55 Million | 35.12% |
| Common Stock | CN¥229.15 Million | 11.91% |
| Other Components | CN¥1.02 Billion | 52.97% |
| Total Equity | CN¥1.92 Billion | 100.00% |
Shandong Sinobioway Biomedicine Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Sinobioway Biomedicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Borussia Dortmund GmbH & Co KGaA
XETRA:BVB
|
$335.00 Million |
|
Viemed Healthcare Inc
NASDAQ:VMD
|
$335.11 Million |
|
Beijing Integrity Technology Co. Ltd. A
SHG:688244
|
$335.11 Million |
|
Swarmer, Inc Common Stock
NASDAQ:SWMR
|
$335.14 Million |
|
MVB Financial Corp
NASDAQ:MVBF
|
$334.87 Million |
|
Interarch Building Products Limited
NSE:INTERARCH
|
$334.85 Million |
|
Dateline Resources Ltd
AU:DTR
|
$334.76 Million |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
$334.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Sinobioway Biomedicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,068,467,729 to 1,923,634,393, a change of -144,833,336 (-7.0%).
- Net loss of 137,313,572 reduced equity.
- Dividend payments of 177,360 reduced retained earnings.
- Other comprehensive income decreased equity by 169,400,534.
- Other factors increased equity by 162,058,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-137.31 Million | -7.14% |
| Dividends Paid | CN¥177.36K | -0.01% |
| Other Comprehensive Income | CN¥-169.40 Million | -8.81% |
| Other Changes | CN¥162.06 Million | +8.42% |
| Total Change | CN¥- | -7.00% |
Book Value vs Market Value Analysis
This analysis compares Shandong Sinobioway Biomedicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 7.46x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.46 | CN¥3.47 | x |
| 2008-12-31 | CN¥0.58 | CN¥3.47 | x |
| 2009-12-31 | CN¥0.61 | CN¥3.47 | x |
| 2010-12-31 | CN¥0.84 | CN¥3.47 | x |
| 2011-12-31 | CN¥2.66 | CN¥3.47 | x |
| 2012-12-31 | CN¥2.49 | CN¥3.47 | x |
| 2013-12-31 | CN¥2.64 | CN¥3.47 | x |
| 2014-12-31 | CN¥1.97 | CN¥3.47 | x |
| 2015-12-31 | CN¥4.65 | CN¥3.47 | x |
| 2016-12-31 | CN¥3.74 | CN¥3.47 | x |
| 2017-12-31 | CN¥4.33 | CN¥3.47 | x |
| 2018-12-31 | CN¥4.17 | CN¥3.47 | x |
| 2019-12-31 | CN¥3.50 | CN¥3.47 | x |
| 2020-12-31 | CN¥3.21 | CN¥3.47 | x |
| 2021-12-31 | CN¥3.62 | CN¥3.47 | x |
| 2022-12-31 | CN¥3.62 | CN¥3.47 | x |
| 2023-12-31 | CN¥3.14 | CN¥3.47 | x |
| 2024-12-31 | CN¥8.39 | CN¥3.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Sinobioway Biomedicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.10%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.14x
- Recent ROE (-7.14%) is below the historical average (12.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 38.88% | 21.75% | 1.57x | 1.14x | CN¥24.24 Million |
| 2008 | 31.90% | 20.90% | 1.23x | 1.24x | CN¥25.43 Million |
| 2009 | 45.35% | 27.51% | 1.30x | 1.27x | CN¥45.85 Million |
| 2010 | 39.62% | 28.42% | 1.18x | 1.18x | CN¥52.52 Million |
| 2011 | 9.96% | 27.19% | 0.36x | 1.03x | CN¥-251.66K |
| 2012 | 12.25% | 30.23% | 0.39x | 1.03x | CN¥15.83 Million |
| 2013 | 11.92% | 27.75% | 0.41x | 1.05x | CN¥14.21 Million |
| 2014 | 10.87% | 25.53% | 0.41x | 1.03x | CN¥6.54 Million |
| 2015 | 12.00% | 29.16% | 0.36x | 1.16x | CN¥41.78 Million |
| 2016 | 16.91% | 33.02% | 0.47x | 1.09x | CN¥170.75 Million |
| 2017 | 13.60% | 33.41% | 0.29x | 1.40x | CN¥102.75 Million |
| 2018 | -3.48% | -14.41% | 0.15x | 1.56x | CN¥-371.09 Million |
| 2019 | 2.74% | 11.17% | 0.17x | 1.48x | CN¥-167.81 Million |
| 2020 | -9.25% | -70.78% | 0.11x | 1.15x | CN¥-407.66 Million |
| 2021 | 11.35% | 67.29% | 0.15x | 1.15x | CN¥32.18 Million |
| 2022 | -0.62% | -4.11% | 0.12x | 1.20x | CN¥-253.23 Million |
| 2023 | -16.07% | -77.35% | 0.18x | 1.13x | CN¥-539.31 Million |
| 2024 | -7.14% | -38.10% | 0.16x | 1.14x | CN¥-329.68 Million |
Industry Comparison
This section compares Shandong Sinobioway Biomedicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,536,896,341
- Average return on equity (ROE) among peers: 9.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Sinobioway Biomedicine Co Ltd (002581) | CN¥1.99 Billion | 38.88% | 0.11x | $334.99 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $692.59 Million | 2.04% | 3.57x | $642.98 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.57% | 0.95x | $376.71 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $377.25 Million | 11.95% | 0.42x | $5.22 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.67 Billion |
| Wedge Industrial Co Ltd (000534) | $760.85 Million | 18.95% | 0.28x | $1.86 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $7.04 Billion | 22.50% | 0.52x | $13.65 Billion |
| Hainan Haiyao Co Ltd (000566) | $292.94 Million | 7.42% | 0.73x | $1.08 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $299.61 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.71 Billion | 7.43% | 1.93x | $964.78 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.09 Billion | 21.79% | 0.11x | $3.21 Billion |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more